SCHEMBL14712876

SCHEMBL14712876

CCN1C(=O)C(=C/C=C/c2ccc(C)cc2)C(=O)N(CC)C1=S

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 13/20 0.59
KMT2A Q03164 11/20 0.59
MEN1 O00255 9/20 0.59
ALDH1A1 P00352 8/20 0.59
POLB P06746 4/20 0.59
L3MBTL1 Q9Y468 4/20 0.59
HTT P42858 4/20 0.59
HPGD P15428 2/20 0.59
KDM4E B2RXH2 2/20 0.59
THRB P10828 1/20 0.59
MDM2 Q00987 1/20 0.59
KDM4C Q9H3R0 1/20 0.59
MAPK1 P28482 8/20 0.49
TNFRSF1A P19438 4/20 0.49
LMNA P02545 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
NPC1 O15118 1/20 0.49
TDP1 Q9NUW8 4/20 0.41
PKM P14618 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14712905 0.87 MAPT (0.57) MAPTKMT2AMEN1ALDH1A1POLB
SCHEMBL14712957 0.87 MAPT (0.57) MAPTKMT2AMEN1ALDH1A1POLB
SCHEMBL14712965 0.87 MAPT (0.64) MAPTKMT2AMEN1ALDH1A1POLB
SCHEMBL14712975 0.85 METAP1 (0.56) MAPTKMT2AMEN1ALDH1A1POLB
SCHEMBL16543009 0.85 MAPT (0.55) MAPTKMT2AMEN1ALDH1A1POLB
SCHEMBL14712900 0.81 MAPT (0.56) MAPTKMT2AMEN1ALDH1A1POLB
SCHEMBL14305633 0.80 APP (0.63) MAPTKMT2AMEN1ALDH1A1POLB
SCHEMBL4906101 0.80 APP (0.63) MAPTKMT2AMEN1ALDH1A1POLB
SCHEMBL14712964 0.79 MAPT (0.61) MAPTKMT2AMEN1ALDH1A1POLB
SCHEMBL14712960 0.79 MAPT (0.57) MAPTKMT2AMEN1ALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-9994554-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-06-12 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2018-05-17 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-9878998-B2 Barbiturate and thiobarbiturate compounds for use in cancer therapy NUHOPE LLC (US) 2018-01-30 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY CONNOR, JAMES R. 2015-03-05 US disclosed
WO-2013024447-A1 COMPOUNDS FOR USE IN CANCER THERAPY NUHOPE, LLC (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134691-A1 BARBITURATE AND THIOBARBITURATE COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAX MAPT 2828/4885KMT2A 2749/4885MEN1 2410/4885
US-20150065531-A1 COMPOUNDS FOR USE IN CANCER THERAPY MGMT, BCL2, BAK1 MAPT 3272/4885KMT2A 3262/4885MEN1 1885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.